Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20231657 | 0.91 | HRH3 (0.49) | KDM4ELMNAKMT2ATDP1HRH3 | |
| SCHEMBL15223818 | 0.91 | KDM4E (0.51) | KDM4ELMNAKMT2ATDP1HRH3 | |
| SCHEMBL23155759 | 0.89 | KDM4E (0.54) | KDM4ELMNAKMT2ATDP1HRH3 | |
| SCHEMBL91688 | 0.86 | CARM1 (0.52) | KDM4EKMT2ATDP1HRH3SIGMAR1 | |
| SCHEMBL11351863 | 0.84 | SIGMAR1 (0.50) | KDM4ELMNAKMT2ATDP1HRH3 | |
| SCHEMBL22560503 | 0.82 | SIGMAR1 (0.53) | KDM4ETDP1HRH3SIGMAR1RECQL | |
| SCHEMBL26156913 | 0.82 | SIGMAR1 (0.53) | KDM4ETDP1HRH3SIGMAR1RECQL | |
| SCHEMBL20326014 | 0.81 | HRH3 (0.50) | KDM4ELMNAKMT2ATDP1HRH3 | |
| SCHEMBL20234908 | 0.81 | KDM4E (0.49) | KDM4ELMNAKMT2ATDP1HRH3 | |
| SCHEMBL20231633 | 0.81 | KDM4E (0.48) | KDM4ELMNAKMT2ATDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | KDM4E 1438/4885LMNA 2706/4885KMT2A 1473/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | KDM4E 3116/4885LMNA 1887/4885KMT2A 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.